Skip to main content

Advertisement

SpringerLink
Log in

186Re-HEDP for metastatic bone pain in breast cancer patients

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Two-thirds of patients with metastatic cancer suffer from pain. Pain originating from skeletal metastases is the most common form of cancer-related pain. Bone pain, often exacerbated by pressure or movement, limits the patient’s autonomy and social life. Pain palliation with bone-seeking radiopharmaceuticals has proven to be an effective treatment modality in patients with metastatic bone pain. These bone-seeking radiopharmaceuticals are extremely powerful in treating scattered painful bone metastases, for which external beam radiotherapy is impossible because of the large field of irradiation. 186Re-hydroxyethylidene diphosphonate (HEDP) is a potentially useful radiopharmaceutical for this purpose, having numerous advantageous characteristics. Bone marrow toxicity is limited and reversible, which makes repetitive treatment safe. Studies have shown encouraging clinical results of palliative therapy using 186Re-HEDP, with an overall response rate of ca. 70% in painful bone metastases. It is effective for fast palliation of painful bone metastases from various tumours and the effect tends to last longer if patients are treated early in the course of their disease. 186Re-HEDP is at least as effective in breast cancer patients with painful bone metastases as in patients with metastatic prostate cancer. It is to be preferred to radiopharmaceuticals with a long physical half-life in this group of patients, who tend to have more extensive haematological toxicity since they have frequently been pretreated with bone marrow suppressive chemotherapy. This systemic form of radionuclide therapy is simple to administer and complements other treatment options. It has been associated with marked pain reduction, improved mobility in many patients, reduced dependence on analgesics, and improved performance status and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20:66–74.

    CAS  PubMed  Google Scholar 

  2. Mathieu L, Chevalier P, Galy G, Berger M. Preparation of rhenium-186 labelled EHDP and its possible use in the treatment of osseous neoplasms. Int J Appl Radiat Isot 1979; 30:725–727.

    Article  CAS  PubMed  Google Scholar 

  3. Deutsch E, Libson K, Vanderheyden JL, Ketring AR, Maxon HR. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B 1986; 13:465–477.

    CAS  PubMed  Google Scholar 

  4. de Klerk JM, van Dijk A, het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992; 33:646–651.

    PubMed  Google Scholar 

  5. de Klerk JM, Zonnenberg BA, het Schip AD, et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21:1114–1120.

    PubMed  Google Scholar 

  6. de Klerk JM, Zonnenberg BA, Krouwer HG, et al. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment. J Nucl Med 1996; 37:465–467.

    PubMed  Google Scholar 

  7. de Klerk JM, het Schip AD, Zonnenberg BA, et al. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996; 37:244–249.

    PubMed  Google Scholar 

  8. Englaro EE, Schroder LE, Thomas SR, et al. Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. Clin Nucl Med 1992; 17:41–44.

    CAS  PubMed  Google Scholar 

  9. de Klerk JM, het Schip AD, Zonnenberg BA, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations. J Nucl Med 1994; 35:1423–1428.

    PubMed  Google Scholar 

  10. Han SH, de Klerk JM, Tan S, et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with186Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002; 43:1150–1156.

    CAS  PubMed  Google Scholar 

  11. Maxon HR III, Thomas SR, Hertzberg VS, et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22:33–40.

    PubMed  Google Scholar 

  12. de Klerk JM, van Dieren EB, het Schip AD, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 1996; 37:38–41.

    PubMed  Google Scholar 

  13. Israel O, Keidar Z, Rubinov R, et al. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186-etidronate. J Clin Oncol 2000; 18:2747–2754.

    CAS  PubMed  Google Scholar 

  14. Maxon HR III, Schroder LE, Thomas SR, et al. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990; 176:155–159.

    PubMed  Google Scholar 

  15. Sciuto R, Tofani A, Festa A, Giannarelli D, Pasqualoni R, Maini CL. Short- and long-term effects of186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000; 41:647–654.

    CAS  PubMed  Google Scholar 

  16. Han SH, Zonneberg BA, de Klerk JM, et al.186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med 1999; 40:639–642.

    CAS  PubMed  Google Scholar 

  17. Quirijnen JM, Han SH, Zonnenberg BA, et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 1996; 37:1511–1515.

    CAS  PubMed  Google Scholar 

  18. Sciuto R, Festa A, Pasqualoni R, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001; 66:101–109.

    Article  CAS  PubMed  Google Scholar 

  19. Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C. Evaluation of toxicity and efficacy of186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 2000; 41:1689–1694.

    CAS  PubMed  Google Scholar 

  20. Palmedo H, Bender H, Dierke-Dzierzon C, et al. Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases. Clin Nucl Med 1999; 24:643–648.

    Article  CAS  PubMed  Google Scholar 

  21. Limouris GS, Shukla SK, Condi-Paphiti A, et al. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases. Anticancer Res 1997; 17:1767–1772.

    CAS  PubMed  Google Scholar 

  22. Schoeneich G, Palmedo H, Dierke-Dzierzon C, Muller SC, Biersack HJ. Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results. Scand J Urol Nephrol 1997; 31:445–448.

    CAS  PubMed  Google Scholar 

  23. Hauswirth AE, Palmedo H, Dierke-Dzierzon C, Biersack HJ, Krebs D. Pain therapy in multiple bone metastases in breast carcinoma with rhenium 186 HEDP [in German]. Zentralbl Gynakol 1998; 120:83–86.

    CAS  PubMed  Google Scholar 

  24. Kucuk NO, Ibis E, Aras G, et al. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Ann Nucl Med 2000; 14:239–245.

    CAS  PubMed  Google Scholar 

  25. Tennvall J, Abrahamsson PA, Ahlgren G, et al. Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma. Scand J Urol Nephrol 2000; 34:188–193.

    Article  CAS  PubMed  Google Scholar 

  26. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28:788–798.

    CAS  PubMed  Google Scholar 

  27. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases [in German]. Nuklearmedizin 2000; 39:146–151.

    CAS  PubMed  Google Scholar 

  28. Guerra UP, Englaro E, Cattaruzzi E. Palliative therapy with rhenium-186-HEDP for bone metastases of breast cancer. Tumori 1997; 83:560–562.

    CAS  PubMed  Google Scholar 

  29. Limouris G, Shukla SK, Manetou A, et al. Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer. Anticancer Res 1997; 17:1699–1704.

    CAS  PubMed  Google Scholar 

  30. Virotta G, Medolago G, Arrigoni S, Butti I, Bertocchi C. Rhenium-186 hydroxyethylidene diphosphonate for treatment of painful osseous metastases from mammary carcinoma. Tumori 1997; 83:563–565.

    CAS  PubMed  Google Scholar 

  31. Holle LH, Humke U, Trampert L, Ziegler M, Kirsch CM, Oberhausen E. Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP). Urologe A 1997; 36:540–547.

    Article  CAS  PubMed  Google Scholar 

  32. Giannakenas C, Kalofonos HP, Apostolopoulos DJ, Zarakovitis J, Kosmas C, Vassilakos PJ. Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol 2000; 23:83–88.

    Article  CAS  PubMed  Google Scholar 

  33. McCready VR, O’Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med Mol Imaging 2002; 29:1271–1275.

    Article  CAS  PubMed  Google Scholar 

  34. O’Sullivan JM, McCready VR, Flux G, et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 2002; 86:1715–1720.

    CAS  PubMed  Google Scholar 

  35. Bushnell DL, Madsen M, Kahn D, Nathan M, Williams RD. Enhanced uptake of99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents. Nucl Med Commun 1999; 20:875–881.

    CAS  PubMed  Google Scholar 

  36. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62:3120–3125.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands

    Marnix G. E. H. Lam, John M. H. de Klerk & Peter P. van Rijk

  2. Department of Nuclear Medicine, Meander Medical Center, Amersfoort, The Netherlands

    John M. H. de Klerk

Authors
  1. Marnix G. E. H. Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. H. de Klerk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter P. van Rijk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marnix G. E. H. Lam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lam, M.G.E.H., de Klerk, J.M.H. & van Rijk, P.P. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging 31 (Suppl 1), S162–S170 (2004). https://doi.org/10.1007/s00259-004-1539-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1539-4

Keywords

Search

Navigation